Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 7Genitourinary 2Thoracic 1Gynecologic 1Breast 1

Conditions

Urinary Bladder Neoplasms 9Prostatic Neoplasms 9Breast Neoplasms 8Pancreatic Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Uterine Cervical Neoplasms 5Stomach Neoplasms 5Ovarian Neoplasms 5Colorectal Neoplasms 5Urologic Neoplasms 4Neoplasms 4Esophageal Neoplasms 4Endometrial Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Urethral Neoplasms 3Thyroid Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Salivary Gland Neoplasms 3Rectal Neoplasms 3Lung Neoplasms 3Gallbladder Neoplasms 3Colonic Neoplasms 3Breast Neoplasms, Male 3Vulvar Neoplasms 2Vipoma 2Vaginal Neoplasms 2Uterine Neoplasms 2Thyroid Carcinoma, Anaplastic 2

Interventions

pembrolizumab 3Trastuzumab 2Nivolumab 2tucatinib 1regorafenib 1pertuzumab 1niraparib 1milademetan 1dostarlimab 1cobimetinib 1brigimadlin 1atezolizumab 1alectinib 1Vemurafenib 1Tomography, X-Ray Computed 1Ramucirumab 1Radiation 1Positron-Emission Tomography 1Paclitaxel 1Magnetic Resonance Imaging 1HhAntag691 1Fulvestrant 1Erlotinib Hydrochloride 1Clinical Trials, Phase II as Topic 1Carboplatin 1Brachytherapy 1Antibodies 1AZD9833 1AZD5305 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Trastuzumab × Genitourinary × Clear all
NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Seagen Inc.

Phase 2 Active not recruiting
217 enrolled 19 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

Phase 2 Completed
673 enrolled 22 charts
GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡